Pages that link to "Q46038843"
Jump to navigation
Jump to search
The following pages link to Nishit B. Modi (Q46038843):
Displaying 50 items.
- Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies (Q28208386) (← links)
- Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation (Q28376544) (← links)
- Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects (Q29041701) (← links)
- Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. (Q34562839) (← links)
- Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation (Q34565008) (← links)
- Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. (Q35009428) (← links)
- Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers. (Q36467274) (← links)
- Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials. (Q37054013) (← links)
- Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease. (Q37233228) (← links)
- Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-en (Q37275476) (← links)
- Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease (Q37343974) (← links)
- Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation. (Q39102210) (← links)
- Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa (Q39150129) (← links)
- A system approach to pharmacodynamics. Input-effect control system analysis of central nervous system effect of alfentanil. (Q41087388) (← links)
- Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease (Q42609024) (← links)
- Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. (Q43916480) (← links)
- Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking (Q44289518) (← links)
- Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. (Q46038779) (← links)
- Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles (Q46070670) (← links)
- Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles (Q46228939) (← links)
- Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder (Q46419553) (← links)
- The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats (Q46450766) (← links)
- Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium (Q46607001) (← links)
- Dapoxetine and paroxetine for the treatment of premature ejaculation (Q46971903) (← links)
- Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end? (Q48449294) (← links)
- Pharmacokinetics, distribution, metabolism, and excretion of the dual reuptake inhibitor [(14)C]-nefopam in rats (Q50251124) (← links)
- Application of a variable direction hysteresis minimization approach in describing the central nervous system pharmacodynamic effects of alfentanil in rabbits (Q51638535) (← links)
- Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil (Q51644780) (← links)
- Application of neural networks to pharmacodynamics (Q51657438) (← links)
- Pharmacodynamic system analysis of the biophase level predictor and the transduction function (Q51684029) (← links)
- An algorithm for constrained deconvolution based on reparameterization. (Q52426591) (← links)
- Optimal extravascular dosing intervals. (Q52444789) (← links)
- Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. (Q53912240) (← links)
- Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers. (Q55059545) (← links)
- Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease. (Q55339111) (← links)
- A System Approach to Pharmacodynamics. Plasma Iron Mobilization by Endogenous Erythropoietin in the Sheep Fetus; Evidence of Threshold Response in Spontaneous Hypoxemia (Q61636089) (← links)
- Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules (Q64796999) (← links)
- Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines (Q71403148) (← links)
- Phenobarbital removal characteristics of three brands of activated charcoals: a system analysis approach (Q72380199) (← links)
- Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males (Q72901884) (← links)
- Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins (Q73143449) (← links)
- Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin (Q73779375) (← links)
- Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens (Q74339441) (← links)
- Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications (Q74405548) (← links)
- Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome (Q77956562) (← links)
- Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers (Q79830141) (← links)
- Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: Impact of age and effects of a high-fat meal (Q80142358) (← links)
- Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys (Q80430110) (← links)
- Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations (Q91884586) (← links)
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera (Q126717581) (← links)